Once again, Evaluate Vantage provides the latest insights and expert perspectives on new developments in the PD-(L)1 inhibitor landscape. The last few months have been all about the clinical readouts, including the Tigit failure and the latest on Keytruda.
.
HIGHLIGHTS INCLUDE:
A look at how follow-on PD-(L)1 inhibitor go-to-market strategies have landed so far.
News on a brand-new immuno-oncology mechanism in the US.
Insights on upcoming catalysts including a regulatory decision on Astrazeneca’s tremelimumab
A summary of all the recent approvals in the US, EU, China and Japan.
